Anti-PD-1 and programmed death-ligand 1 (PD-L1) mAbs, which have radically changed the current treatment scenario for NSCLC, seem ineffective in EGFR-mutated patients. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.